麦澜德公告，公司股票交易连续三个交易日内（2025年8月8日、8月11日、8月12日）收盘价格涨幅偏离 值累计达到30%，属于股票交易异常波动情形。公司主要从事盆底及妇产康复领域相关医疗器械产品的 研发、生产、销售，主要产品涵盖盆底及妇产康复、生殖康复和抗衰、运动康复及耗材和信息化产品。 目前运动康复产品收入占比较小，暂未对公司业绩产生重大影响。 ...

Group 1 - The core viewpoint of the articles highlights the performance and market position of 麦澜德 in the medical device industry, showcasing its recent achievements and financial metrics [1][2] - 麦澜德's stock closed at 29.62 yuan, with a rolling PE ratio of 28.17, marking a new low in 32 days, and a total market capitalization of 29.62 billion yuan [1] - The company ranks 62nd in the medical device industry, which has an average PE ratio of 49.20 and a median of 36.56 [1][2] Group 2 - For Q1 2025, 麦澜德 reported revenue of 1.18 billion yuan, reflecting a year-on-year increase of 13.36%, and a net profit of 3985.97 million yuan, up by 9.85%, with a gross margin of 70.85% [2] - The company specializes in the research, production, sales, and services of products related to pelvic floor and obstetric rehabilitation, focusing on women's health [1] - 麦澜德 has been recognized as a "national manufacturing single champion" and is the first national-level specialized and innovative "little giant" enterprise in its field, indicating strong market competitiveness and innovation capabilities [1]